Nasus Pharma Ltd. NSRX 深 沪
等待开盘 08-16 09:30:00 美东时间
8.10
+0.050
+0.62%
华盛通- 最 高8.30
- 今 开8.00
- 成交量 6.89万股
- 最 低 7.96
- 昨 收 8.05
- 总市值 7298.10万
- 52周最高 9.51
- 市盈率 静 --
- 换手率 0.77%
- 52周最低 7.96
- 委 比 66.67%
- 总股本 901.00万
- 历史最高 9.51
- 量 比 0
- 振 幅 4.22%
- 历史最低 7.96
- 每 手 1
- 风险率 0.13%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多一周IPO丨引爆市场！银诺医药-B一度飙涨近300%，天岳先进预计下周三上市！
牛股频出！银诺医药-B首日涨超200%！创年内港股新股首日涨幅纪录；天岳先进超购倍数超2400倍！预计下周三上市；“币圈新贵”Bullish上市首日涨超80%>>
08-15 17:13
新股首日 | “第三极”交易所 MIAX IPO首日开盘大涨近30%，报29.68美元
“第三极”交易所 MIAX IPO首日开盘大涨近30%，报29.68美元，公司最新市值超23亿美元>>
08-15 01:03
Nasus Pharma Announces Closing of Initial Public Offering
<p>Nasus Pharma Ltd., a clinical-stage pharmaceutical company, has completed its initial public offering of 1.25 million ordinary shares at $8.00 per share, raising $10 million. The shares began trading on the NYSE American under the ticker "NSRX." The company plans to use the proceeds for its intranasal epinephrine program and general corporate purposes. Laidlaw & Company and Craft Capital Management acted as joint bookrunners. The offering was ...
08-14 20:05
Nasus Pharma Prices $10M Initial Public Offering Of 1.25M Ordinary Shares At $8.00 Per Share
The Company intends to use the net proceeds from the initial public offering for furthering the development of its intranasal Epinephrine program, including, manufacturing scale-up and additional Phase 2 studies, and the
08-13 19:38
一周IPO丨中慧生物暗盘飙涨162%，中签一手赚超4000港元；“减肥药概念”银诺医药招股中
中慧生物暗盘飙涨162%，中签一手赚超4000港元；Firefly首日大涨34%，市值近85亿美元；“减肥药概念”银诺医药招股中；美国第四大期权交易所MIAX预计下周上市>>
08-09 12:32
一周财经日历丨重磅财报周！腾讯京东季报轮番登场；美国7月CPI/PPI携手“恐怖数据”来袭
重磅财报周！腾讯京东季报轮番登场；美国7月CPI/PPI携手“恐怖数据”来袭；中慧生物、银诺医药下周上市>>
08-09 12:21
NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
NeuroStar TMS therapy has demonstrated strong efficacy in treating adolescents and young adults with depression, as shown by data from the world's largest depression outcomes database. Approximately 70% of patients reported significant improvement, with results comparable to those in adult populations, emphasizing the importance of completing the full course of treatment.
07-30 12:32
